Results of a new analysis shows that the sodium glucose co-transporter 2 (SGLT2) inhibitor, Invokana (canagliflozin; Janssen) was associated with significantly greater improvements in blood glucose control compared to dipeptidyl peptidase-4 (DPP-4) inhibitors. The real-world findings, the first to compare the effectiveness of an SGLT2 inhibitor with DPP-4 inhibitors, were published in Current Medical Research & Opinion.
A retrospective cohort analysis matched 2766 patients prescribed Invokana (100mg or 300mg daily) with an equal number of similar patients prescribed DPP-4 inhibitors. Each patient had 6 months of baseline data and 9 months of follow-up data after starting therapy. Those treated with Invokana had a mean reduction in A1C of 0.92% compared to baseline, versus a mean reduction of 0.63% among those treated with a DPP-4 inhibitor (p < 0.001). Additionally, a significantly greater percentage of patients taking Invokana achieved treatment goals of A1C less than 8% and less than 7%. Similar results were observed in a post-hoc analysis of those treated with Invokana versus the DPP-4 inhibitor, sitagliptin.
“This real world analysis complements findings from the pivotal trials that informed the approval of Invokana, as it provides insights to physicians on how these medicines are performing post-approval for people living with type 2 diabetes,” said study co-author Richard Aguilar, M.D., Medical Director of Diabetes Nation. “These new findings are important in light of the need to identify therapeutic options with the best potential for achieving treatment goals, especially since they are estimated to remain unmet for up to one-half of people with type 2 diabetes.”
Invokana is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
For more information visit invokanahcp.com.